Loading...
Loading...
PMCB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,409.5K |
| Operating I/L | -1,409.5K |
| Other Income/Expense | 4,199.4K |
| Interest Income | 894.2K |
| Pretax | 2,789.9K |
| Income Tax Expense | -894.2K |
| Net Income/Loss | 2,789.9K |
PharmaCyte Biotech, Inc. is a biotechnology company specializing in developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. The company's proprietary Cell-in-a-Box technology serves as a platform for developing therapies for advanced and inoperable pancreatic cancer, as well as diabetes, including encapsulated genetically modified insulin-producing cells. Additionally, PharmaCyte Biotech is working on cancer therapies utilizing constituents of the cannabis plant. The company has research agreements with the University of Technology, Sydney, and the University of Northern Colorado to advance its diabetes and cancer treatment developments.
